Real-World Data Champion Robert Califf Nominated for FDA Commissioner
Dr. Califf is a staunch advocate for the use of real-world data (RWD) and real-world evidence (RWE) in the clinical trial ecosystem, with a long history of leveraging RWD and RWE to transform the life sciences community.
COTA Collaborates with University of Chicago Medicine and UT Southwestern on Research To Be Presented at the American Society for Hematology’s Annual Meeting & Exposition
Four abstracts will be showcased at the American Society for Hematology’s (ASH) Annual Meeting & Exposition from December 11–14, 2021, in Atlanta, Georgia. COTA has the most comprehensive hematology oncology real-world data that is curated under the close guidance of leading oncologists and hematology specialists.
Rewriting the Oncology Patient’s Journey with Real-World Data
Life science stakeholders are committed to making the path to positive outcomes less frightening and convoluted for patients. With breakthrough treatments and innovative therapies targeted to the toughest of cancers, the industry has made significant progress with guiding patients toward longer, healthier lives.
As Acceptance of Real-World Data Broadens, COTA Makes Strategic Leadership Hires to Support Company Growth
At COTA, Laura and the research and quality team will work to expand the organization’s research footprint and develop enhanced quality and regulatory compliance standards to support healthcare providers and life sciences customers in leveraging real-world data to advance cancer care.
With New FDA Guidance on Real-World Data, What’s the Next Step for Clinical Trials?
In September 2021, the FDA published new draft guidance as part of its ongoing efforts to explore the use of real-world data (RWD) and real-world evidence (RWE) within its regulatory decision-making process.
Roche is Validating the Utility of Real-World Evidence as a comparator to Single-arm Clinical Trials
A new study from Roche finds concerns around real-world evidence as a comparator to single-arm trials may be unfounded.
COTA, Inc. announces Ritu Bahal has joined the company to serve as Chief Financial Officer
As CFO, Ritu will oversee all aspects of COTA’s financial strategy as it enters the next phase of growth. She will support COTA’s overall mission of bringing clarity to cancer care by devising and implementing sound financial strategies to maximize revenue growth and operational efficiencies, increasing financial transparency and engaging with investors.
Growing Our Team During the Pandemic
Thanks to the pandemic, remote work is more collaborative, but hiring and onboarding new employees has its share of challenges. Thankfully we were able to pivot and COTA is proud of the process we’re using to recruit new employees.
Study: Cancer Patients and Their Families Frustrated with Slow Pace of Drug and Treatment Innovation
COTA announced findings from a study that found 66 percent of cancer patients and their immediate families surveyed think that the speed of clinical trials aimed at driving much-needed innovations in cancer treatments and therapies remains far too slow. The study, which surveyed 1,110 Americans who’ve either had cancer or who’ve had someone in their immediate family with cancer, also found that the recent rapid development of multiple COVID-19 vaccines heightened this belief.
COTA to Accelerate Life Sciences Impact With Addition of Christine Kawiecki from IBM Watson Health
With more than 25 years of healthcare experience, Christine Kawiecki joins the COTA, Inc. team to support business growth as life sciences companies are increasingly turning to real-world data to accelerate drug development in a post-pandemic world.
